Seaport Therapeutics, Inc. (SPTX)
NASDAQ: SPTX · Real-Time Price · USD
22.39
+1.27 (6.01%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Seaport Therapeutics Employees
Seaport Therapeutics had 58 employees as of June 30, 2026.
Employees
58
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,322,190
Market Cap
1.20B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 58 | - | - |
| Mar 31, 2026 | 58 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MannKind | 592 |
| Replimune Group | 465 |
| MeiraGTx Holdings | 393 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| Vor Biopharma | 76 |
SPTX News
- 7 days ago - Seaport Therapeutics Slides: Corporate presentation - Filings
- 7 days ago - Seaport Therapeutics Slides: Conference presentation - Filings
- 8 days ago - Seaport Therapeutics to Participate in September Investor Conferences - Business Wire
- 13 days ago - PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
- 13 days ago - Seaport Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 13 days ago - Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint - TheFly
- 13 days ago - Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
- 13 days ago - Seaport Therapeutics Slides: Corporate presentation - Filings